The new therapy for diabetic maculopathy was finally approved in Italy (January 2017) as a class H therapy, i.e. paid for by the national health service. It is a cortisone-based drug (fluocinolone) that is administered by intravitreal injection. It has proven effective in the treatment of diabetes-related maculopathy (Diabetic Macular Edema). Unlike other drugs used for intravitreal injection which require repeated injections, it has prolonged effectiveness. In fact, it releases low-dose cortisone inside the eye for 36 months. A single intravitreal injection for approximately three years, unlike other drugs which require injections every one/two months. Diabetic maculopathy is a chronic disease whose progress is linked to the state of glycometabolic compensation, i.e. how well the diabetes is treated. The first objective of those suffering from diabetic maculopathy must be to control their diabetes well , however today Iluvien is a valid option for these patients. This cortisone-based therapy has two important side effects on the eye: it causes cataracts and can increase pressure, inducing glaucoma. So it is not a therapy that can be administered to everyone. Only an expert ophthalmologist can advise you whether this drug is indicated or not in your specific case. It comes from the United States of America and is recommended only for patients with diabetic macular edema who have already had cataract surgery and who have already used cortisone-based therapy without having had an increase in eye pressure. Dr Badalà uses this therapy in diabetic maculopathy in the Milan office.